<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569673</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0186F</org_study_id>
    <secondary_id>GOG-0186F</secondary_id>
    <secondary_id>CDR0000577866</secondary_id>
    <nct_id>NCT00569673</nct_id>
  </id_info>
  <brief_title>Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase II Evaluation of Docetaxel (NSC #628503) Plus Trabectedin (Yondelis®), R279741, IND # 101018) With Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and trabectedin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Colony-stimulating factors, such as G-CSF and pegfilgrastim, may help the immune
      system recover from the side effects of chemotherapy. Giving combination chemotherapy
      together with G-CSF or pegfilgrastim may kill more tumor cells.

      PURPOSE: This phase II trial is studying the side effects and how well giving docetaxel and
      trabectedin together with G-CSF or pegfilgrastim works in treating patients with recurrent or
      persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To estimate the antitumor activity of docetaxel plus trabectedin in patients with
           persistent or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cavity
           cancer primarily through the frequency of objective tumor responses.

        -  To determine the nature and degree of toxicity of docetaxel plus trabectedin in this
           cohort of patients.

      Secondary

        -  To estimate the progression-free survival and overall survival of patients treated with
           docetaxel and trabectedin.

      OUTLINE: Patients receive docetaxel IV over 1 hour and trabectedin IV over 3 hours on day 1.
      Patients also receive pegfilgrastim subcutaneously (SC) on day 1 OR filgrastim (G-CSF) IV
      over 15-30 minutes or SC once daily beginning on day 1 and continuing until blood counts
      recover. Treatment repeats every 3 weeks in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed every 3 months for 2 years and
      then every 6 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>every other cycle for the first 6 months; then every 3 months x 2; then</time_frame>
    <description>Response is measured according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.0):
Complete Response (CR) is disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.
Partial Response (PR) is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD.
Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.
Stable Disease is any condition not meeting the above criteria.
Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Severity of Adverse Events as Assessed by CTCAE v3.0</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Progression-free Survival and Overall Survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">71</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabectedin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
             cavity carcinoma

               -  Recurrent or persistent disease

          -  Measurable disease, defined as at least 1 lesion that can be accurately measured in at
             least 1 dimension (longest dimension to be recorded) ≥ 20 mm by conventional
             techniques or ≥ 10 mm by spiral CT scan

          -  Must have at least 1 &quot;target lesion&quot; to be used to assess response on this protocol as
             defined by RECIST criteria

               -  Tumors within a previously irradiated field will be designated as &quot;non-target&quot;
                  lesions unless progression is documented or a biopsy is obtained to confirm
                  persistence at least 90 days following completion of radiation therapy

          -  Must have had 1 prior platinum-based chemotherapeutic regimen for management of
             primary disease containing carboplatin, cisplatin, or another organoplatinum compound
             and the initial treatment may have included high-dose therapy, consolidation, or
             extended therapy administered after surgical or non-surgical assessment

               -  Patients are allowed, but not required to receive, 2 additional cytotoxic
                  regimens for management of recurrent or persistent disease with no more than 1
                  non-platinum, non-taxane regimen

               -  Patients who have received only 1 prior cytotoxic regimen (platinum-based regimen
                  for management of primary disease), must meet 1 of the following criteria:

                    -  Platinum-free interval of &lt; 12 months

                    -  Progressed during platinum-based therapy

                    -  Persistent disease after a platinum-based therapy

          -  Not eligible for a higher priority GOG protocol (i.e., any active GOG Phase III
             protocol for the same patient population)

        PATIENT CHARACTERISTICS:

          -  GOG performance status (PS) 0-2 or after receiving 1 prior treatment regimen (GOG PS
             0-1 after receiving 2 or more prior regimens)

          -  Platelet count ≥ 100,000/mm³

          -  ANC count ≥ 1,500/mm³

          -  Hemoglobin &gt; 9 g/dL

          -  Creatinine ≤ 1.5 times upper limit normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

          -  CPK normal

          -  Bilirubin or direct bilirubin normal

          -  Alkaline phosphatase normal

          -  Neuropathy (sensory and motor) ≤ grade 1

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active infection requiring antibiotics (except for uncomplicated UTI)

          -  No other invasive malignancy within the past 5 years, except nonmelanoma skin cancer

          -  No known active liver disease or hepatitis

          -  Willing and able to have a central venous catheter

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from effects of recent surgery, radiotherapy, or chemotherapy

          -  At least 1 week since prior hormonal therapy directed at the malignant tumor

               -  Continuation of hormone replacement therapy allowed

          -  At least 3 weeks since other prior therapy, including biological and immunological
             therapy directed at the tumor

          -  Chimeric or human or humanized monoclonal antibodies must be discontinued for at least
             6 weeks prior to study entry

          -  No investigational therapy within the past 30 days

          -  No prior therapy with docetaxel and/or trabectedin

          -  No radiation to more than 25% of marrow-bearing areas

          -  No prior cancer treatment that contraindicates protocol therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley J. Monk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristine M. Zanotti, MD</last_name>
    <affiliation>MacDonald Physicians, Incorporated at University MacDonald Womens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center - Burbank</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tunnell Cancer Center at Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31403-3089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinsdale Hematology Oncology Associates</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Indianapolis Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Cancer Program at Union Hospital</name>
      <address>
        <city>Elkton MD</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Cancer Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center at Cox Medical Center South</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-5636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center at Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Cancer Care Center at MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center at Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health - West Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David L. Rike Cancer Center at Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Cancer Center at Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake/University Ireland Cancer Center</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenfeld Cancer Center at Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center at Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Gynecologic Oncology Associates</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Mar;120(3):459-63. doi: 10.1016/j.ygyno.2010.11.012. Epub 2010 Dec 7.</citation>
    <PMID>21144560</PMID>
  </results_reference>
  <results_reference>
    <citation>Monk, M BJ, Sill M, Walker JL, et al.: Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG). [Abstract] J Clin Oncol 28 (Suppl 15): A-5046, 2010.</citation>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <results_first_submitted>May 27, 2014</results_first_submitted>
  <results_first_submitted_qc>May 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2014</results_first_posted>
  <last_update_submitted>May 27, 2014</last_update_submitted>
  <last_update_submitted_qc>May 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel Plus Trabectedin</title>
          <description>Docetaxel 60 mg/m2 IV over 1 hour followed by trabectedin (YONDELIS„µ, R279741) formerly referred to as, ET-743) 1.1 mg/m2 over 3 hours with Filgrastim (G-CSF, NSC #614629), Pegfilgrastim (G-CSF, NSC #725961) or Sargramostim (GM-CSF, NSC #613795) every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71">Total number participants enrolled on study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71">Total number participants that are eligible and evaluable.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total number eligible and evaluable</population>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel Plus Trabectedin</title>
          <description>Docetaxel 60 mg/m2 IV over 1 hour followed by trabectedin (YONDELIS„µ, R279741) formerly referred to as, ET-743) 1.1 mg/m2 over 3 hours with Filgrastim (G-CSF, NSC #614629), Pegfilgrastim (G-CSF, NSC #725961) or Sargramostim (GM-CSF, NSC #613795) every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cell Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma, Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clear Cell Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endometrioid Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Epithelial Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serous Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response</title>
        <description>Response is measured according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.0):
Complete Response (CR) is disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.
Partial Response (PR) is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD.
Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.
Stable Disease is any condition not meeting the above criteria.
Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy6</description>
        <time_frame>every other cycle for the first 6 months; then every 3 months x 2; then</time_frame>
        <population>Total number eligible and evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel Plus Trabectedin</title>
            <description>Docetaxel 60 mg/m2 IV over 1 hour followed by trabectedin (YONDELIS„µ, R279741) formerly referred to as, ET-743) 1.1 mg/m2 over 3 hours with Filgrastim (G-CSF, NSC #614629), Pegfilgrastim (G-CSF, NSC #725961) or Sargramostim (GM-CSF, NSC #613795) every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response</title>
          <description>Response is measured according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.0):
Complete Response (CR) is disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.
Partial Response (PR) is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD.
Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.
Stable Disease is any condition not meeting the above criteria.
Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy6</description>
          <population>Total number eligible and evaluable</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indeterminate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Severity of Adverse Events as Assessed by CTCAE v3.0</title>
        <time_frame>up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Progression-free Survival and Overall Survival</title>
        <time_frame>up to 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study entry until disease progression or study withdrawal. Patients will then be monitored for delayed toxicity for a 5 year period.</time_frame>
      <desc>Activation through Mar 31, 2011, Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (CTCAE v3.0) are utilized for defining and grading specific adverse events reported through the AdEERS system. Beginning Apr 1, 2011, CTCAE v 4.0 will be utilized for AE reporting through the AdEERS system. AEs are reported here using only CTCAEv3.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel Plus Trabectedin</title>
          <description>Docetaxel 60 mg/m2 IV over 1 hour followed by trabectedin (YONDELIS„µ, R279741) formerly referred to as, ET-743) 1.1 mg/m2 over 3 hours with Filgrastim (G-CSF, NSC #614629), Pegfilgrastim (G-CSF, NSC #725961) or Sargramostim (GM-CSF, NSC #613795) every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Edema: Head And Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, Gi - Ileum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Necrosis, Gi - Colon/Cecum/Appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Obstruction, Gi - Small Bowel Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Death No Ctcae Term - Disease Progression Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Chest /Thorax Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf W/Gr 3 Or 4 Anc: Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Skin(Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Catheter-Related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Abdomen Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Gr 3 Or 4 Anc: Bladder (Urinary)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Gi - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Abdomen Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Edema: Trunk/Genital</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Edema: Head And Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>S/N Arrhythmia: Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia - Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>S/N Arrhythmia: Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>S/N Arrhythmia: Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cardipulmonary Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis Middle Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hearing (Without Monitoring Program)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Flashing Lights/Floaters</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Eyelid Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Distention</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Incontinence, Anal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mucositis (Functional/Sympt) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mucositis (Clinical Exam) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Urethra</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Chest /Thorax Nos</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Chest Wall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Throat/Pharynx/Larynx</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-Limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Joint</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Bone</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Pain Nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Rectum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Abdominal Pain Nos</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Cardiac/ Heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain: Muscle</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf W/Gr 3 Or 4 Anc: Skin (Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Upper Airway Nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Lung(Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Eye Nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Oral Cavity-Gums</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Skin(Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Catheter-Related</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Urinary Tract Nos</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Abdomen Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colitis, Infectious (Eg.C. Difficile)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Gr 3 Or 4 Anc: Oral Cavity-Gums</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Vagina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Bladder (Urinary)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Gr 3 Or 4 Anc: Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inf W/Gr 3 Or 4 Anc: Urinary Tract Nos</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Ast</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gfr</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cholesterol,serum High</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ggt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Alt</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cpk</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bicarbonate, Serum-Low</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/St: Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Muscle Weakness - Whole Body/Generalized</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Muscle Weakness - Extremity-Lower</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Involuntary Movement</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neuropathy-Motor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary Electrolyte Wasting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Incontinence, Urinary</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vaginal Dryness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary: Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nasal/Paranasal Reactions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Voice Changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hair Loss/Alopecia (Scalp Or Body)</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Inr</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gu - Urinary Nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gu - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Pulmonary - Nose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Abdomen Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessalyn Reboy</name_or_title>
      <organization>NRG Oncology, Statistics and Data Management Center, Buffalo Office</organization>
      <phone>716-845-7738</phone>
      <email>ReboyJ@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

